Short radiation with chemo and immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have rectal cancer that has not spread beyond the rectum (no distant or lateral lymph node spread).
- You must not have had radiation therapy or immunotherapy before.
- You must not have certain immune system or endocrine (hormone) diseases, like lupus or thyroid problems.
- You need good overall health, especially for your heart, lungs, liver, and kidneys.
- You must be willing to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests a shorter course of radiation therapy that avoids lymph nodes, followed by an immunotherapy drug, for patients with stage II or III rectal cancer that has not spread. It aims to improve outcomes while reducing side effects.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Hear when a new Rectal Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.